e-Therapeutics looks for £40m for PhII cancer trial
This article was originally published in Scrip
Executive Summary
UK-based e-Therapeutics plans to raise £40 million through an issue of 125 million new shares in a bid to give the company enough cash to advance its cancer candidate, ETS2101 (dexanabinol) into Phase II.